SymBio Pharmaceuticals Limited [4582.T]
TOKYO, May 01 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) reported the exercise status of its 58th and 66th warrants for April 2026. The 58th warrant was issued to CVI Investments, Inc.
In June 2022, while the 66th warrant was issued to EVO FUND in August 2025. In April, 5,000 shares were delivered under the 66th warrant, with an average exercise price of ¥106 per share. A total of 5,000 warrants were exercised during the month.
As of the end of April, there were 20,000 unexercised warrants remaining out of the total issuance of 50,000. In contrast, no exercises occurred under the 58th warrant in April. Additionally, the company noted that the 67th warrant issued to EVO FUND in August 2025 had its exercise price adjusted similarly to the 66th warrant but remains non-exerciseable until August 13, 2027 due to contractual agreements.
The company adhered to the exercise limitations set forth by the Tokyo Stock Exchange's listing regulations, maintaining an exercise ratio below the mandated threshold.
🟢 Confidence: High AI-translated content.